All In Biotech

NDA 020958 · Kenvue Brands

Pepcid Complete

Calcium Carbonate, Famotidine, Magnesium Hydroxide · Oral · Histamine-2 Receptor Antagonist

Last checked: Nov 20, 2026Latest source record: Sep 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Oct 16, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

596

144 Phase 3, 25 recruiting

FAERS reports

2,416

816 serious, 74 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 25, 2026.

Use relieves heartburn associated with acid indigestion and sour stomach

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PEPCID COMPLETE · CALCIUM CARBONATE 800MG; FAMOTIDINE 10MG; MAGNESIUM HYDROXIDE 165MG · TABLET, CHEWABLE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbonate" as an intervention, any sponsor and status, largest first.

All 596 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease483
  • drug ineffective312
  • acute kidney injury257
  • renal failure174
  • end stage renal disease133
  • gastrooesophageal reflux disease133
  • off label use100
  • product use in unapproved indication100
  • wrong technique in product usage process98
  • incorrect dose administered97
  • therapeutic response unexpected93
  • product physical issue83

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20055
20065
20079
200812
200937
201016
201118
201214
20137
201410
2015165
2016150
2017232
2018254
2019334
2020208
2021207
2022143
2023172
2024110
2025170
2026134

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,455 on PubMed

Sponsor: Kenvue Brands

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.